Skip to content

US · AVBP · BIOTECHNOLOGY

ArriVent BioPharma, Inc. (AVBP) intrinsic value and stock valuation

$10.52as of 2026-11-21 · Mkt cap 1.44B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ArriVent BioPharma, Inc. DCF and intrinsic value

InvestorsCraft values AVBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVBP’s statements →

ArriVent BioPharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newtown Square, PA 19073 arrivent.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-166.31M
20212025
Free cash flow
-$-160.59M
20212025
Total equity
$307.2M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-177.53M-$-94.31M-$-74.59M-$-36.91M-$-8.7M
Net income-$-166.31M-$-80.49M-$-69.33M-$-36.91M-$-51.61M
EPSd-$-4.32M-$-2.56M-$-2.17M-$-1.1M-$-40.32M
Operating cash flow-$-160.59M-$-70.21M-$-55.84M-$-43.63M-$-12.59M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-160.59M-$-70.21M-$-55.84M-$-43.63M-$-12.59M
Total assets$333.2M$274.9M$163.1M$182.8M$43M
Total debt$10K$180K$320K$140K$0.00
Net debt-$-45.53M-$-74.12M-$-150.07M-$-163.23M-$-37.28M
Total equity$307.2M$257.7M$151.3M$174.5M$41.2M
Cash and short-term investments$312.8M$218.9M$150.4M$163.4M$37.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$153.4M$79M$64.9M$30.4M$6.43M
Selling, general and administrative expenses$24.2M$15.3M$9.71M$6.47M$2.26M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$177.5M$94.3M$74.6M$36.9M$8.7M
Cost and expenses$177.5M$94.3M$74.6M$36.9M$8.7M
Interest income$11.2M$13.8M$5.26M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$36.9M$0.00
Ebitda-$-166.31M-$-80.49M-$-69.33M$0.00-$-51.61M
Operating income-$-177.53M-$-94.31M-$-74.59M-$-36.91M-$-8.7M
Total other income/expenses, net$11.2M$13.8M$5.26M$0.00-$-42.91M
Income before tax-$-166.31M-$-80.49M-$-69.33M-$-36.91M-$-51.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-166.31M-$-80.49M-$-69.33M-$-36.91M-$-51.61M
Weighted average shares outstanding$38.5M$31.5M$32M$33.5M$1.28M
Weighted average diluted shares outstanding$38.5M$31.5M$32M$33.5M$1.28M
Balance sheet
20252024202320222021
Cash and short-term investments$312.8M$218.9M$150.4M$163.4M$37.3M
Net receivables$60K$500K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$332.9M$227M$160M$182.6M$43M
Property, plant and equipment, net$10K$150K$290K$140K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$47.7M$0.00$0.00$0.00
Total non-current assets$270K$48M$3.13M$210K$90K
Total assets$333.2M$274.9M$163.1M$182.8M$43M
Accounts payable$5.93M$3.78M$4.53M$3.09M$290K
Short-term debt$10K$160K$140K$130K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$26M$17.3M$11.6M$8.36M$1.82M
Long-term debt$0.00$10K$180K$10K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$10K$180K$10K$0.00
Capital lease obligations$10K$180K$320K$140K$0.00
Total liabilities$26M$17.3M$11.8M$8.37M$1.82M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-404.64M-$-238.33M-$-157.84M-$-88.51M-$-51.61M
Accumulated other comprehensive income (loss)$10K-$-210K$0.00$0.00-$0.00
Total equity$307.2M$257.7M$151.3M$174.5M$41.2M
Total investments$267.3M$192.3M$0.00$0.00$0.00
Total debt$10K$180K$320K$140K$0.00
Net debt-$-45.53M-$-74.12M-$-150.07M-$-163.23M-$-37.28M
Cash flow statement
20252024202320222021
Net income-$-166.31M-$-80.49M-$-69.33M-$-36.91M-$-51.61M
Depreciation and amortization-$-3.03M$0.00$0.00$0.00$0.00
Stock-based compensation$12.5M$3.21M$900K$420K$70K
Change in working capital-$-3.77M$7.07M$12.6M-$-7.15M-$-3.94M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.14M-$-750K$1.38M$2.8M$290K
Net cash provided by operating activities-$-160.59M-$-70.21M-$-55.84M-$-43.63M-$-12.59M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-71.23M-$-192.47M$0.00$0.00-$-40M
Common stock issued$202.6M$186M$350K$0.00$89.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$203.1M$186.6M$42.9M$169.7M$89.9M
Net change in cash-$-28.75M-$-76.1M-$-12.98M$126.1M$37.3M
Cash at end of period$45.5M$74.3M$150.4M$163.4M$37.3M
Operating cash flow-$-160.59M-$-70.21M-$-55.84M-$-43.63M-$-12.59M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-160.59M-$-70.21M-$-55.84M-$-43.63M-$-12.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ArriVent BioPharma, Inc.

        ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

        CEO
        Zhengbin Yao
        Employees
        77
        Beta
        1.30

        Explore

        Frequently asked questions

        What is the intrinsic value of ArriVent BioPharma, Inc. (AVBP)?

        InvestorsCraft does not currently publish an intrinsic value for AVBP. How the IC value is calculated.

        Is AVBP undervalued?

        InvestorsCraft does not publish an undervaluation signal for AVBP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.